Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
KOOL's Cash-to-Debt is ranked higher than
96% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. KOOL: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
KOOL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.87  Med: 1768.89 Max: No Debt
Current: No Debt
Equity-to-Asset 0.70
KOOL's Equity-to-Asset is ranked higher than
62% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. KOOL: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
KOOL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45  Med: 0.81 Max: 0.9
Current: 0.7
0.45
0.9
Piotroski F-Score: 5
Altman Z-Score: -5.61
Beneish M-Score: -4.09
WACC vs ROIC
10.64%
-35.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -77.33
KOOL's Operating Margin % is ranked lower than
75% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. KOOL: -77.33 )
Ranked among companies with meaningful Operating Margin % only.
KOOL' s Operating Margin % Range Over the Past 10 Years
Min: -92.63  Med: -45.79 Max: -12.12
Current: -77.33
-92.63
-12.12
Net Margin % -297.49
KOOL's Net Margin % is ranked lower than
85% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. KOOL: -297.49 )
Ranked among companies with meaningful Net Margin % only.
KOOL' s Net Margin % Range Over the Past 10 Years
Min: -297.49  Med: -41.14 Max: -10.97
Current: -297.49
-297.49
-10.97
ROE % -118.69
KOOL's ROE % is ranked lower than
91% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. KOOL: -118.69 )
Ranked among companies with meaningful ROE % only.
KOOL' s ROE % Range Over the Past 10 Years
Min: -118.69  Med: -27.29 Max: -13.56
Current: -118.69
-118.69
-13.56
ROA % -81.63
KOOL's ROA % is ranked lower than
86% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. KOOL: -81.63 )
Ranked among companies with meaningful ROA % only.
KOOL' s ROA % Range Over the Past 10 Years
Min: -81.63  Med: -21.57 Max: -10.6
Current: -81.63
-81.63
-10.6
ROC (Joel Greenblatt) % -629.75
KOOL's ROC (Joel Greenblatt) % is ranked lower than
80% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. KOOL: -629.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KOOL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -629.75  Med: -136.59 Max: -36.5
Current: -629.75
-629.75
-36.5
3-Year Revenue Growth Rate -39.30
KOOL's 3-Year Revenue Growth Rate is ranked lower than
89% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. KOOL: -39.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KOOL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.3  Med: -4.5 Max: 20.7
Current: -39.3
-39.3
20.7
3-Year EBITDA Growth Rate 27.50
KOOL's 3-Year EBITDA Growth Rate is ranked higher than
83% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. KOOL: 27.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
KOOL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39  Med: -6.1 Max: 27.6
Current: 27.5
-39
27.6
3-Year EPS without NRI Growth Rate 25.80
KOOL's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. KOOL: 25.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
KOOL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.7  Med: -7.2 Max: 28.4
Current: 25.8
-35.7
28.4
GuruFocus has detected 2 Warning Signs with Cesca Therapeutics Inc $KOOL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KOOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

KOOL Guru Trades in Q4 2015

Jim Simons 57,029 sh (New)
» More
Q1 2016

KOOL Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q2 2016

KOOL Guru Trades in Q2 2016

Jim Simons 30,635 sh (New)
» More
Q3 2016

KOOL Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3821
Compare:NAS:ETRM, OTCPK:VICA, OTCPK:BSGM, OTCPK:TLTFF, OTCPK:BIQLF, OTCPK:SNWV, OTCPK:ZMSPF, NAS:MDVX, OTCPK:LCTC, OTCPK:VASO, OTCPK:DIZTF, AMEX:ELMD, NAS:MGCD, NAS:RWLK, OTCBB:NAOV, NAS:AMDA, OTCPK:NIMU, OTCPK:BTCY, OTCPK:SMLR, OTCPK:GIDYL » details
Traded in other countries:THRN.Germany,
Cesca Therapeutics Inc is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It develops and manufactures automated blood and bone marrow processing systems.

Cesca Therapeutics Inc formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets. The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.

Ratios

vs
industry
vs
history
PB Ratio 0.85
KOOL's PB Ratio is ranked higher than
90% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. KOOL: 0.85 )
Ranked among companies with meaningful PB Ratio only.
KOOL' s PB Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.48 Max: 6.7
Current: 0.85
0.16
6.7
PS Ratio 0.88
KOOL's PS Ratio is ranked higher than
82% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. KOOL: 0.88 )
Ranked among companies with meaningful PS Ratio only.
KOOL' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 1.6 Max: 19.37
Current: 0.88
0.36
19.37
Current Ratio 2.01
KOOL's Current Ratio is ranked lower than
62% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. KOOL: 2.01 )
Ranked among companies with meaningful Current Ratio only.
KOOL' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 4.81 Max: 16.85
Current: 2.01
1.45
16.85
Quick Ratio 1.50
KOOL's Quick Ratio is ranked lower than
57% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. KOOL: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
KOOL' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 3.42 Max: 15.88
Current: 1.5
0.86
15.88
Days Inventory 135.18
KOOL's Days Inventory is ranked lower than
51% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. KOOL: 135.18 )
Ranked among companies with meaningful Days Inventory only.
KOOL' s Days Inventory Range Over the Past 10 Years
Min: 119.78  Med: 152.7 Max: 181.75
Current: 135.18
119.78
181.75
Days Sales Outstanding 81.12
KOOL's Days Sales Outstanding is ranked lower than
62% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. KOOL: 81.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
KOOL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.82  Med: 96.66 Max: 116.79
Current: 81.12
61.82
116.79
Days Payable 80.80
KOOL's Days Payable is ranked higher than
65% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. KOOL: 80.80 )
Ranked among companies with meaningful Days Payable only.
KOOL' s Days Payable Range Over the Past 10 Years
Min: 44.89  Med: 88.74 Max: 164.16
Current: 80.8
44.89
164.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.60
KOOL's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. KOOL: -53.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KOOL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.6  Med: -11.9 Max: 0
Current: -53.6
-53.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.55
KOOL's Price-to-Median-PS-Value is ranked higher than
81% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. KOOL: 0.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KOOL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 3.3 Max: 15.24
Current: 0.55
0.33
15.24
Earnings Yield (Greenblatt) % -117.81
KOOL's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. KOOL: -117.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KOOL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -705.47  Med: 170.85 Max: 7391.6
Current: -117.81
-705.47
7391.6

More Statistics

Revenue (TTM) (Mil) $13.58
EPS (TTM) $ -9.07
Beta0.30
Short Percentage of Float4.64%
52-Week Range $1.85 - 7.39
Shares Outstanding (Mil)9.89

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 12 12 13
EPS ($) -1.18 -1.27 -1.27
EPS without NRI ($) -1.18 -1.27 -1.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
Insiders Roundup: Vera Bradley Tops List Dec 30 2016 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 05 2009 

More From Other Websites
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 17 2017
CESCA THERAPEUTICS INC. Financials Feb 17 2017
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 13 2017
Cesca Therapeutics Reports Second Quarter Fiscal 2017 Financial Results and Provides Business Update Feb 13 2017
Q2 2017 Cesca Therapeutics Inc Earnings Release - After Market Close Feb 13 2017
Cesca Therapeutics to Announce Second Quarter Fiscal 2017 Results on February 13, 2017 Feb 09 2017
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 17 2017
Cesca Therapeutics Appoints Dr. Joseph Thomis to Its Board of Directors Jan 17 2017
CESCA ANNOUNCES FDA APPROVAL OF IDE SUPPLEMENT FOR PHASE III CLINICAL TRIAL Jan 05 2017
Cesca Announces FDA Approval of IDE Supplement for Phase III Clinical Trial Jan 05 2017
CESCA THERAPEUTICS TO PRESENT AT THE 9TH ANNUAL BIOTECH SHOWCASE Jan 03 2017
Cesca Therapeutics to Present at the 9th Annual Biotech Showcase Jan 03 2017
Insiders Keep Buying as Market Wraps on 2016: Tronic, Six Flags, Virtu Financial, Cesca Therapeutics... Jan 01 2017
Nvidia (NVDA) Can’t Shake Citron, Cempra (CEMP) Slammed by FDA Rejection, Plus 3 Other Major... Dec 29 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 20 2016
Cesca Submits IDE Supplement for CLI Pivotal Trial Dec 05 2016
Cesca Therapeutics to Present at the 9th Annual LD Micro Main Event Dec 02 2016
Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q1, 2017 By the Numbers : November 23, 2016 Nov 23 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits Nov 22 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K/A, Triggering Events That Accelerate or Increase a Direct... Nov 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)